MIMEDX GROUP, INC. (MDXG) stock intrinsic value fair value estimate & owner earnings analysis

MiMedx (Marietta, Georgia) makes placental-tissue products for two markets. Wound products such as EPIFIX and EPICORD are used on chronic wounds, mostly for Medicare patients. Surgical products such as AMNIOFIX, AMNIOEFFECT and the licensed HELIOGEN particulate are used in operating rooms. Until 2025 this was a highly profitable business: 2025 sales were $418.6 million, two-thirds of it Wound, and owner earnings were about $0.53 a share. What changed. On 1 January 2026 Medicare began paying a single flat rate of about $127 per square centimetre for skin-substitute products. Wound sales fell 61% in the second quarter of 2026 to $25.1 million, while Surgical grew 15% to $39.3 million. Total sales were $64.4 million against $98.6 million a year earlier, gross margin fell to 69% from 81%, and the company lost $14.8 million. Medicare's proposal for 2027 keeps the flat rate. The company cut about $40 million of annual costs in the second quarter, and Wound sales grew 11% from the first quarter as customers adjusted. The second change is the acquisition of Sanara MedTech, signed on 29 July 2026 and approved by Sanara shareholders on 30 September; antitrust clearance is the main remaining step. MiMedx will pay about $303 million in cash and issue about 4.35 million shares. Sanara sells CellerateRX and BIASURGE into surgery, had 2025 sales of $103 million and grew 14% in the first half of 2026. To pay for it, MiMedx is borrowing $300 million for six years from Hayfin at a floating rate of SOFR plus 6.25% (about 10% today). Because the deal is signed and committed, we value the company as it will look after closing. How we measured earnings. Owner earnings start from operating cash flow, remove working-capital swings, deduct stock compensation as a real cost and deduct only maintenance capital spending. For 2023 onward we use continuing operations only. We corrected 2021 and 2022 onto the same basis; the earlier figures mixed in cash from discontinued businesses. The 2023–2025 record ($0.24, $0.36, $0.53 a share) describes a business that no longer exists, because the pricing behind it ended on 1 January 2026, and two loss-making quarters confirm it. We therefore build the level from the business as it now stands rather than from that history. Earlier years (2016–2022) were dominated by the accounting restatement and its legal costs and are not used. Owner earnings grew 47% in 2025; year one of every case below is far lower, for the dated reason above. Today's earning power. For MiMedx alone we start from the second-quarter cost base, remove the one-time severance and an unusual $5.3 million bad-debt charge (wound customers hurt by the payment change), and add the rest of the announced savings. At the June sales run rate of about $280 million a year, that gives roughly $24 million a year of cash earnings before stock pay, or about $12 million after stock pay of about $10 million and capital spending. Sanara earned about $13.5 million a year on the same basis in the first half of 2026. Removing Sanara's separate public-company costs adds about $3 million. The combined business therefore produces about $28 million a year before interest, about $0.19 a share. The new loan's interest will be about $30 million a year, so the combined company starts out earning roughly its interest bill and no more. What it owes. After repaying the old Citizens loan, paying the cash price, retiring Sanara's $46.5 million loan and an estimated $20 million of deal and financing fees, we expect about $300 million of debt against about $35 million of cash beyond operating needs: net debt of about $265 million. Because the loan costs about 4 percentage points more than a long government bond, we add about $60 million for that extra cost over its six-year life (less in the bull case, more in the bear case). The total is about $325 million, or about $2.15 a share. Base case, -$0.46 a share. The combined business earns $28 million a year (about $20 million in year one, after integration costs) for ten years and then fades to nothing over the following ten, because these products carry no long patent life and we can name nothing that sustains them indefinitely beyond the sales relationships. We credit no growth. Surgical has grown at double-digit rates for six quarters and Sanara for three years, but both depend on winning share and launching products, which has not yet happened. On that basis the business is worth about $256 million and owes about $325 million. The company appears to owe about $70 million more than it is worth, roughly $0.46 a share, unless surgical growth continues. Bear case, -$1.94 a share. Wound pricing keeps eroding. Sanara's and MiMedx's surgical sales suffer one downturn of the kind seen in the 2020 shutdown, when MiMedx sales fell 17% in a year and elective procedures stopped for a quarter. We model one year of losses of $25 million and a slow recovery to $12 million a year. A further risk is that MiMedx loses the court case over whether its AXIOFILL particulate can be sold without a full biologic licence. With interest of about $30 million a year, the cash buffer would be gone within two years, and the company would likely need covenant waivers, costlier borrowing or new shares at low prices. The business would be worth about $46 million against debt of about $340 million. The company would owe roughly $290 million more than it is worth. Bull case, $5.18 a share. Surgical keeps growing at 14% a year, slowing to 3% by year seven. Sanara grows from 12% slowing to 3%. OsStic, Sanara's bone adhesive with FDA breakthrough designation, launches in 2027 as planned. Wound sales hold at today's level. Each extra dollar of sales earns 40 cents, so combined sales reach about $595 million and cash earnings before interest about $120 million by 2036. They then hold for five years and fade over ten. The business would be worth about $1.09 billion against about $310 million of debt. The pre-deal figures we published before are not comparable. They valued MiMedx with about $0.80 a share of net cash. The signed Sanara purchase turns that into about $2.15 a share of net debt, and that change, not a change in operating results, is what moves the values down. How we set the margin of safety price. We are fairly sure of the earnings level today, because it comes from two reported quarters after the payment change and a filed cost-reduction plan. We are not sure of what follows: every positive value depends on surgical growth continuing for years. The worst plausible outcome is a lender-driven restructuring. The loan is floating-rate and carries covenants. Earnings cover the interest only barely. Sales depend heavily on Medicare payment rules that changed overnight once and that CMS says it will keep revisiting. Placental-tissue products are not hard assets a lender could sell. If we are wrong about the two things we are most likely to be wrong about, the outcome swings from roughly -$2 to above $5 a share. Those two things are whether surgical growth continues and whether the combined company can cut debt. The business pays no dividend, so nothing is paid over the holding period. On today's evidence no positive margin-of-safety price applies. If, after closing, the company shows two consecutive quarters in which cash earnings after stock pay and capital spending exceed interest, and net debt falls below $250 million, the debt would be shrinking and the growth would be paying for it. On that condition the margin-of-safety price is $0.50 a share. From that price, even a business that only holds its earnings and slowly pays down debt implies 20% a year over three to five years. Any continuation of surgical growth would add to what the cases imply. Not reconciled from the filings. Third-quarter 2026 results are not yet reported. Transaction fees, the Sanara loan prepayment premium and the Hayfin covenant levels are not disclosed; we estimated the fees at about $20 million. Sanara figures come from its own unaudited quarterly releases.